Astrazeneca Share Discussion Threads

[alphorn] 20/8/2021 10:50

Ronapreve, a monoclonal antibody treatment, produced by Roche & Regeneron has received UK approval today. It is administered either by injection or infusion and acts to stop coronavirus from gaining access to the cells of the respiratory system.
It joins Veklury (remdesivir) produced by Gilead.

Don't know how widespread they will be used, or how expensive? If you remember, Trump received the experimental Regeneron drug.

[alphorn] 20/8/2021 10:22

The drug could be suitable for patients for whom a vaccine is not recommended. It offers up to a full year of protection from Covid and is delivered by intramuscular injection. (FT)

[maxk] 20/8/2021 09:14

A snippet..



9:02am

No severe cases or deaths reported in phase three trials of AstraZeneca antibody treatment

In the phase three trials of AstraZeneca's antibody treatment, PROVENT, a statistically significant reduction in the incidence of symptomatic Covid-19 was achieved.

The trial showed that the antibody treatment reduced the risk of developing symptomatic Covid by 77 per cent compared to a placebo.

Additionally, the company reported that there were no cases of severe Covid-19 and no virus-related deaths in the those treated with the combination of the two antibodies.

The antibody combination, called AZD7442, is reportedly the first antibody combination, non-vaccine, that can potentially provide long-lasting protection and has demonstrated the prevention of Covid-19 in a clinical trial.

The trial included 5,197 participants in a 2 to 1 randomisation of the antibody treament to placebo.

[mike24] 16/8/2021 11:00

Israel faces fourth wave, despite 420,000 treated with third jab
of which a number have still caught c19.
18/8
US c19 deaths reach 1000 a day, yet US deaths from heart related problems
are nearly 2000 a day, in most cases a stent will resolve the problem, but
the after care required is often in the region of taking a dozen different medications
many of which need to be taken for life

dangers of aspirin highlighted (poss bleeding in the brain) in recent medical,
the stomach can be protected Lansoprazole

[beckers2008] 16/8/2021 10:49

Catching Up, well it is summer!

12/08/2021.
Analysts at JP Morgan resumed their coverage of AstraZeneca at 'overweight', telling clients they saw a "re-rating opportunity".

Indeed, with approximately 20% upside now on offer, JP Morgan also named the shares its UK large-cap top-pick.

The company's share price, with an implied core price-to-earnings multiple of 15.5 and 13.5 times' for 2022 and 2023, was failing to reflect the company's superior growth outlook.

"We see Astra's sector discount unwinding, as the Alexion acquisition demonstrates continued strong top-line growth, coupled with significant operating margin expansion and increased free cash flow generation," they added.
That was on top of a "number" of upcoming pipeline catalysts that the broker said could drive long-term upgrades and multiple expansion.
On their 10,000.0p target price, Astra would merely re-rate to a 2023 sector multiple, JP Morgan said.

Among those potential catalysts were phase III data from Lynparza's PROpel front line Prostate cancer trial, ALXN1840 for Wilson's disease and phase III data for Enhertu DESTINY-04 for HER2 intermediate/low breast cancer.

The former two dats sets were expected in the back half of 2021 and the latter in the front half of 2022.

[waldron] 15/8/2021 10:07

GeckotheGlorious
15 Aug '21 - 09:54 - 28169 of 28169
0 1 0
"Sunday papers – Glaxo hits back in Astra Zeneca row"
A legal battle between Britain’s two pharma champions has escalated after Glaxo Smith Kline launched a counter-claim against rival Astra Zeneca.

It revolves around sales of Glaxo’s top-selling cancer drug, Zejula, a treatment for ovarian and other cancers. Astra licenses the underlying technology to Glaxo, and claims it should receive a greater share of Zejula’s sales. It accused Glaxo of breaching the terms of its agreement and has hired accountants KPMG to audit Zejula’s sales. A source suggested the claim could reach hundreds of millions of pounds. Glaxo, led by Dame Emma Walmsley, is defending itself in the High Court. It is demanding a £2.5 million refund from Astra for royalties already paid, claiming it mistakenly paid them on a higher proportion of Zejula’s sales

[the grumpy old men] 13/8/2021 17:39

[United Kingdom] ASTRAZENECA PLC (AZN)

Delayed Quote. Delayed London Stock Exchange - 08/13 04:37:58 pm

8426 GBX +1.53%

[philanderer] 12/8/2021 10:58

JPMORGAN REINITIATES ASTRAZENECA WITH 'OVERWEIGHT' - PRICE TARGET 10,000 PENCE

[ianood] 12/8/2021 00:26

Purchase order in then!

[montyhedge] 11/8/2021 20:58

Below 8000p next week.

[waldron] 11/8/2021 18:12

AstraZeneca PLC said Wednesday that the U.S. Food and Drug Administration has asked for an extra clinical of roxadustat for the treatment of anemia of chronic kidney disease before it can approve the company's new drug application.

The pharmaceutical giant said that it is working with its partner FibroGen Inc. to evaluate the next steps.

AstraZeneca added that the safety and effectiveness of roxadustat has been demonstrated in a Phase 3 program in more than 8,000 patients.

Roxadustat is already approved in a number of countries, including China and Japan, and is under regulatory review in the European Union and other jurisdictions, the company said.



Write to Ian Walker at [e-mail]



(END) Dow Jones Newswires

August 11, 2021 10:03 ET (14:03 GMT)

[la forge] 11/8/2021 16:25

AstraZeneca PLC said Wednesday that the U.S. Food and Drug Administration has asked for an extra clinical of roxadustat for the treatment of anemia of chronic kidney disease before it can approve the company's new drug application.

The pharmaceutical giant said that it is working with its partner FibroGen Inc. to evaluate the next steps.

AstraZeneca added that the safety and effectiveness of roxadustat has been demonstrated in a Phase 3 program in more than 8,000 patients.

Roxadustat is already approved in a number of countries, including China and Japan, and is under regulatory review in the European Union and other jurisdictions, the company said.



Write to Ian Walker at [e-mail]



(END) Dow Jones Newswires

August 11, 2021 10:03 ET (14:03 GMT)

[la forge] 11/8/2021 09:21

EX DIVI TOMORROW

[montyhedge] 09/8/2021 15:07

Every rns seems good news, but Alexion bid, lot of shares to be digested, I think Alexion shareholders who end up with Astra shares may take profits, I see Astra 7500p. Just my view.

[philanderer] 09/8/2021 10:04

MORGAN STANLEY REINITIATES ASTRAZENECA WITH 'OVERWEIGHT' - PRICE TARGET 9,800 PENCE

[waldron] 09/8/2021 08:14

AstraZeneca PLC said Monday that its Forxiga drug has been approved in the European Union for the treatment of chronic kidney disease in adults with or without type 2 diabates.

The British-Swedish drugmaker said the approval is based on positive results from the DAPA-CKD phase three trial.



Write to Sabela Ojea at [e-mail]; @sabelaojeaguix



(END) Dow Jones Newswires

August 09, 2021 02:53 ET (06:53 GMT)

[waldron] 09/8/2021 08:12

AstraZeneca PLC said Monday that its Enhertu cancer treatment achieved positive results at its first phase III head-to-head trial.

The pharmaceutical company said the trial compared Enhertu with trastuzumab emtansine on patients with HER2-positive breast cancer. HER2 protein overexpression is often associated with aggressive disease and a poor prognosis in breast cancer.

An independent committee concluded that the trial met the primary endpoint of progression-free survival, showing improvements for patients with HER2-positive breast cancer.



Write to Jaime Llinares Taboada at [e-mail]; @JaimeLlinaresT



(END) Dow Jones Newswires

August 09, 2021 02:35 ET (06:35 GMT)

[gibbs1] 07/8/2021 09:22

August/12/2021 Ex-dividend day for interim dividend

[descartes244238] 06/8/2021 16:40

The numpty in charge wants to keep giving the vaccine away. No thanks and being sued by the EU wasn't enough for him. Time he was removed

[philanderer] 06/8/2021 00:27

AstraZeneca vaccine 'may give longer immunity' meaning Covid booster jabs could be unnecessary, suggests boss of UK drugs giant

[montyhedge] 05/8/2021 07:56

Overbought, going lower.